We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

74 hedge funds and large institutions have $298M invested in Albireo Pharma Inc in 2019 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 29 increasing their positions, 17 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 17

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

9% more capital invested

Capital invested by funds: $273M → $298M (+$25.7M)

3% more funds holding

Funds holding: 72 → 74 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
74
Holders Change
+2
Holders Change %
+2.78%
% of All Funds
1.61%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
10
Increased
29
Reduced
17
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
+$24M
2
Man Group
Man Group
United Kingdom
+$5.61M
3
BlackRock
BlackRock
New York
+$2.83M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.63M
5
N
Nuveen
North Carolina
+$1.25M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$4.52M
2
ACH
ArrowMark Colorado Holdings
Colorado
-$3.5M
3
AG
Artal Group
Luxembourg
-$1.67M
4
WMSA
Weiss Multi-Strategy Advisers
New York
-$836K
5
TCM
Tekla Capital Management
Massachusetts
-$664K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
51
American International Group
New York
$212K +$25.4K +758 +13%
AllianceBernstein
52
AllianceBernstein
Tennessee
$206K +$214K +6,400 New
MIM
53
MetLife Investment Management
New Jersey
$152K – – –
Bank of America
54
Bank of America
North Carolina
$138K +$47K +1,404 +49%
MLICM
55
Metropolitan Life Insurance Company (MetLife)
New York
$107K – – –
Citigroup
56
Citigroup
New York
$94K +$19.8K +591 +26%
UBS Group
57
UBS Group
Switzerland
$93K +$95.1K +2,844 +11,376%
JP Morgan Chase
58
JP Morgan Chase
New York
$90K +$20.5K +614 +28%
SO
59
STRS Ohio
Ohio
$87K – – –
MAM
60
Meeder Asset Management
Ohio
$65K +$60.2K +1,800 +796%
Legal & General Group
61
Legal & General Group
United Kingdom
$53K – – –
AG
62
Aperio Group
California
$42K +$43.7K +1,306 New
Bank of Montreal
63
Bank of Montreal
Ontario, Canada
$38K -$114K -3,413 -74%
BNP Paribas Financial Markets
64
BNP Paribas Financial Markets
France
$33K -$29.2K -872 -46%
PCM
65
Prelude Capital Management
New York
$26K +$2.14K +64 +8%
CSS
66
Cubist Systematic Strategies
Connecticut
$24K +$25.4K +759 New
AIP
67
Ameritas Investment Partners
Nebraska
$22K – – –
Morgan Stanley
68
Morgan Stanley
New York
$16K -$55.6K -1,663 -77%
DWA
69
Dorsey Wright & Associates
California
$11K +$11.4K +342 New
CCM
70
Cribstone Capital Management
Maine
$10K – – –
Royal Bank of Canada
71
Royal Bank of Canada
Ontario, Canada
$3K – – –
LFASL
72
Lugano Financial Advisors SA (LFA)
Switzerland
$3K +$3.35K +100 New
PMFA
73
Plante Moran Financial Advisors
Michigan
$2K – – –
PFGIA
74
Patriot Financial Group Insurance Agency
Massachusetts
$1K – – –
AAP
75
Ardsley Advisory Partners
Connecticut
– -$245K -7,600 Closed
1 2
3
4

ALBO Hedge Fund Activity: Q2 2019 in Review

74 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q2 2019, worth a combined $298M — up 9.4% from $273M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ALBO positions and 6 closed out — a net gain of 4 holders — while 29 added to existing stakes and 17 trimmed.

The largest buyer was Federated Hermes, adding an estimated $24M. The largest seller was BVF Inc, cutting an estimated $4.52M.

  • 74 institutional investors held Albireo Pharma Inc (ALBO) as of Q2 2019, up from 72 in Q1 2019.
  • Funds reported $298M of Albireo Pharma Inc stock for Q2 2019, up 9.4% quarter-over-quarter.
  • 10 funds opened new Albireo Pharma Inc positions in Q2 2019 and 6 closed out, a net change of +4 holders.
  • The largest Albireo Pharma Inc buyer in Q2 2019 was Federated Hermes, an estimated $24M added.
  • The largest Albireo Pharma Inc seller in Q2 2019 was BVF Inc, an estimated $4.52M sold.

Based on aggregated 13F filings for Q2 2019.